Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Data And FDA Study Filing [Yahoo! Finance]
Krystal Biotech, Inc. (KRYS)
Last krystal biotech, inc. earnings: 11/4 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.krystalbio.com/investors
Company Research
Source: Yahoo! Finance
inhaled delivery of KB407 to the lungs of cystic fibrosis patients with confirmed expression of wild-type CFTR protein and a generally mild-to-moderate safety profile. The company also disclosed that it has submitted the design of its planned repeat-dosing CORAL-3 study to the FDA, signaling an accelerated path toward potentially registrational trials for KB407 and a broader role for its gene therapy platform in respiratory disease. We'll now examine how confirmation of lung CFTR expression at the highest KB407 dose could reshape Krystal Biotech's broader investment narrative. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit To own Krystal Biotech, you need to believe VYJUVEK can keep funding a broader gene therapy pipeline while new programs like KB407 mature. The positive CORAL-1 high dose data strengthens the near term KB407 catalyst by confirming lung CFTR expression, but it does not remove key risks ar
Show less
Read more
Impact Snapshot
Event Time:
KRYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRYS alerts
High impacting Krystal Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
KRYS
News
- Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Citigroup Inc. from $320.00 to $336.00. They now have a "buy" rating on the stock.MarketBeat
- Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Assessing Krystal Biotech (KRYS) Valuation After Positive KB407 Cystic Fibrosis Trial Update [Yahoo! Finance]Yahoo! Finance
- Is Krystal Biotech (KRYS) Still Attractively Priced After Its Strong Multi Year Share Price Run [Yahoo! Finance]Yahoo! Finance
KRYS
Earnings
- 11/3/25 - Beat
KRYS
Sec Filings
- 1/12/26 - Form 8-K
- 1/8/26 - Form 8-K
- 12/23/25 - Form 8-K
- KRYS's page on the SEC website